PL3227325T3 - SELECTIVE COMPOSITIONS OF IL-6 TRANS-SIGNALING INHIBITORS - Google Patents

SELECTIVE COMPOSITIONS OF IL-6 TRANS-SIGNALING INHIBITORS

Info

Publication number
PL3227325T3
PL3227325T3 PL15834723.7T PL15834723T PL3227325T3 PL 3227325 T3 PL3227325 T3 PL 3227325T3 PL 15834723 T PL15834723 T PL 15834723T PL 3227325 T3 PL3227325 T3 PL 3227325T3
Authority
PL
Poland
Prior art keywords
trans
signaling inhibitors
selective compositions
selective
compositions
Prior art date
Application number
PL15834723.7T
Other languages
Polish (pl)
Inventor
Ian Cottingham
Daniel Plaksin
Jérémy DUBOEUF
Original Assignee
Ferring B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring B.V. filed Critical Ferring B.V.
Publication of PL3227325T3 publication Critical patent/PL3227325T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
PL15834723.7T 2014-12-01 2015-12-01 SELECTIVE COMPOSITIONS OF IL-6 TRANS-SIGNALING INHIBITORS PL3227325T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14195726 2014-12-01
PCT/NL2015/050837 WO2016089206A2 (en) 2014-12-01 2015-12-01 Selective il-6-trans-signalling inhibitor compositions

Publications (1)

Publication Number Publication Date
PL3227325T3 true PL3227325T3 (en) 2024-10-07

Family

ID=52000745

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15834723.7T PL3227325T3 (en) 2014-12-01 2015-12-01 SELECTIVE COMPOSITIONS OF IL-6 TRANS-SIGNALING INHIBITORS

Country Status (20)

Country Link
US (3) US10519218B2 (en)
EP (2) EP4356962A3 (en)
JP (2) JP6827941B2 (en)
KR (2) KR20240131465A (en)
CN (1) CN107406491A (en)
CA (1) CA2969314A1 (en)
DK (1) DK3227325T3 (en)
ES (1) ES2981475T3 (en)
FI (1) FI3227325T3 (en)
HR (1) HRP20240581T1 (en)
HU (1) HUE066987T2 (en)
LT (1) LT3227325T (en)
MA (1) MA41116B1 (en)
MD (1) MD3227325T2 (en)
MX (2) MX388268B (en)
PL (1) PL3227325T3 (en)
PT (1) PT3227325T (en)
RS (1) RS65665B1 (en)
SI (1) SI3227325T1 (en)
WO (1) WO2016089206A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS65665B1 (en) 2014-12-01 2024-07-31 Ferring Bv Selective il-6-trans-signalling inhibitor compositions
EP3226888B1 (en) 2014-12-01 2021-04-21 Ferring B.V. Administration of a selective il-6-trans-signalling inhibitor
JP7432506B2 (en) 2017-10-30 2024-02-16 武田薬品工業株式会社 Environmentally compatible surfactants for inactivating lipid enveloped viruses
MX2020005630A (en) * 2017-11-30 2020-08-20 Bio Thera Solutions Ltd Liquid preparation of humanized antibody for treating il-6-related disease.
JP7287611B2 (en) * 2018-02-07 2023-06-06 学校法人日本医科大学 Improved adeno-associated virus vector
JP7781786B2 (en) * 2020-06-10 2025-12-08 フェリング・ベー・フェー Pharmaceutical compounds for treating atherosclerotic cardiovascular disease
WO2022139580A1 (en) 2020-12-22 2022-06-30 Ferring B.V. Blood gene expression biomarkers to predict response in patients with inflammatory bowel diseases
CN114681592A (en) * 2020-12-31 2022-07-01 天境生物科技(杭州)有限公司 Formulations comprising soluble gp130 dimers and methods of use
WO2024011946A1 (en) * 2022-07-12 2024-01-18 I-Mab Biopharma (Hangzhou) Co., Ltd Polypeptide dimers for the treatment of systemic sclerosis

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
JPH04218000A (en) 1990-02-13 1992-08-07 Kirin Amgen Inc Modified polypeptide
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5783672A (en) 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
US6472179B2 (en) * 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
DE19941897B4 (en) 1999-09-02 2006-06-14 GSF - Forschungszentrum für Umwelt und Gesundheit GmbH IL-6 receptor protein, beta chain (gp130) of the IL-6 receptor protein, DNA encoding these proteins, RNA derived therefrom, peptide having amino acids 771-811 of this beta chain or parts thereof, and uses thereof
JP5179689B2 (en) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Enhancing the half-life of antibody-based fusion proteins in the circulation
ES2298106T3 (en) 2000-04-21 2008-05-16 Conaris Research Institute Ag FUSION PROTEINS THAT INCLUDE TWO SOLUBLE GP130 MOLECULES.
CA2447236A1 (en) 2001-05-21 2002-11-28 Nektar Therapeutics Pulmonary administration of chemically modified insulin
WO2003008454A2 (en) 2001-07-18 2003-01-30 Merck Patent Gmbh Glycoprotein vi fusion proteins
US6887687B2 (en) 2001-07-30 2005-05-03 Immunex Corporation Nucleic acids encoding human ataxin-1-like polypeptide IMX97018
JP2004182638A (en) 2002-12-03 2004-07-02 Yakult Honsha Co Ltd Preventive and therapeutic agent for inflammatory disease or malignant tumor
EP1491554A1 (en) 2003-06-23 2004-12-29 CONARIS research institute AG PEGylated soluble gp130-dimers useful as a medicament
EP1630232B1 (en) * 2004-08-27 2008-07-02 CONARIS research institute AG Optimized nucleotide sequences encoding sgp130
EP1801121A1 (en) 2005-12-23 2007-06-27 CONARIS research institute AG Soluble gp130 molecule variants useful as a medicament
EA200870130A1 (en) * 2005-12-30 2009-02-27 Мерк Патент Гмбх ANTIBODIES AGAINST IL-6, PREVENTING BONDING TO GP130 COMPLEX IL-6 AND ALPHA RECEPTOR IL-6
KR20140107702A (en) * 2006-06-30 2014-09-04 코나리스 리써치 인스티튜트 아게 IMPROVED sgp130Fc DIMERS
ES2352561T3 (en) * 2006-06-30 2011-02-21 Conaris Research Institute Ag IMPROVED SGP DIMMERS 130FC.
EP2050759A1 (en) 2007-10-19 2009-04-22 CONARIS research institute AG Soluble gp 130 muteins with improved binding activity
DK2661492T3 (en) 2011-01-06 2018-01-15 Univ Johns Hopkins Method for Preparing Recombinant Glycoproteins with Increased Circuit Half Life in Mammalian Cells
EP3226888B1 (en) 2014-12-01 2021-04-21 Ferring B.V. Administration of a selective il-6-trans-signalling inhibitor
RS65665B1 (en) * 2014-12-01 2024-07-31 Ferring Bv Selective il-6-trans-signalling inhibitor compositions

Also Published As

Publication number Publication date
CA2969314A1 (en) 2016-06-09
DK3227325T3 (en) 2024-07-08
HUE066987T2 (en) 2024-09-28
RS65665B1 (en) 2024-07-31
US20200123226A1 (en) 2020-04-23
LT3227325T (en) 2024-05-27
WO2016089206A3 (en) 2016-07-28
EP4356962A3 (en) 2024-07-24
JP2021073229A (en) 2021-05-13
EP4356962A2 (en) 2024-04-24
MX2021007899A (en) 2021-09-08
MX388268B (en) 2025-03-18
SI3227325T1 (en) 2024-06-28
US20180282396A1 (en) 2018-10-04
CN107406491A (en) 2017-11-28
HRP20240581T1 (en) 2024-07-19
KR20170135818A (en) 2017-12-08
WO2016089206A2 (en) 2016-06-09
MA41116B1 (en) 2024-07-31
EP3227325B1 (en) 2024-04-10
JP2017536848A (en) 2017-12-14
US11306136B2 (en) 2022-04-19
FI3227325T3 (en) 2024-07-10
EP3227325A2 (en) 2017-10-11
JP6827941B2 (en) 2021-02-10
MD3227325T2 (en) 2024-09-30
KR20240131465A (en) 2024-08-30
MA41116A (en) 2017-10-10
ES2981475T3 (en) 2024-10-09
KR102699098B1 (en) 2024-08-27
MX2017007069A (en) 2018-02-09
JP7184936B2 (en) 2022-12-06
US20220275056A1 (en) 2022-09-01
PT3227325T (en) 2024-07-01
US10519218B2 (en) 2019-12-31

Similar Documents

Publication Publication Date Title
IL281638A (en) Compositions of angiotensinogen IRNA and methods of using them
IL263586B (en) Inhibitors of menin-mll interaction
DK3102576T3 (en) DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA
LT3303334T (en) THYROSINKINASE INHIBITORS
HUE042335T2 (en) ROR-gamma dihydropyrrolopyridine inhibitors
EP3377059A4 (en) INHIBITORS OF CXCR2
DK3164380T3 (en) INHIBITORS OF LIGHT-SPECIFIC DEMETHYLASE-1
LT3137169T (en) LYSINE-SPECIFIC DEMETYLASE-1 INHIBITORS
DK3160956T3 (en) Inhibitors of lysine-specific demethylase-1
DK3442972T3 (en) BROMDOMAIN INHIBITORS
LT3191487T (en) COPYPSIN C SPIROCYCLIC INHIBITORS
DK3144001T3 (en) Compositions of selenoorganic compounds and methods of their use
DK3542812T3 (en) GLYCOPEPTIME COMPOSITIONS
DK3341379T3 (en) EZH2 inhibitors
DK3116475T3 (en) DOPA-DECARBOXYLASE INHIBITOR COMPOSITIONS
LT3288944T (en) IMIDAZOPYRAZINones AS INHIBITORS OF PDE1
DK3186242T3 (en) ALFA-AMINO-BETA-CARBOXYMUCONSIDE-SEMIALDEHYDE-DECARBOXYLASE INHIBITORS
DK3132009T3 (en) COURSE OF ACTION
HRP20181441T1 (en) ALDOSTERON SYNTHESIS INHIBITORS
DK3283210T3 (en) COURSE OF ACTION
DK3227325T3 (en) COMPOSITIONS WITH SELECTIVE INHIBITORS OF IL-6 TRANS-SIGNALING
DK3114120T3 (en) TETRAZOLON SUBSTITUTED DIHYDROPYRIDINON-MGAT2 INHIBITORS
DK3240767T3 (en) MICROCAPE-LEADED NITRIFICATION INHIBITOR COMPOSITIONS
DK3204352T3 (en) Inhibitors of lysine-gingipain
IL249674B (en) Quinolizinone derivatives as inhibitors of pi3k